DOCSLIB.ORG

Patient Present Sever Sign Segment Upper Develop Differ Studi Syndrom

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patient Present Sever Sign Segment Upper Develop Differ Studi Syndrom Diseases 1: Acute Disease (544) 2: Pulmonary Embolism (39) acut aml chronic clinic complic diseas group activ associ case clinic diagnos leukaemia leukemia manifest mds mild myeloid diagnosi diagnost factor incid men patient present sever sign mortal platelet preval symptom syndrom transplant patient protein rate risk studi women year 3: Somnambulism (1) 4: Night Terrors (2) adult conserv data depress disord care complex cost decreas famili elderli enhanc increas literatur mean old older peopl potenti releas stimul studi form format increas inform year young younger manag medic member particip person physician potenti practic report stimul target 5: Dog Diseases (124) 6: Myelodysplastic Syndromes (208) asymmetri canin cat deform digit distal acut aml bcr-abl blast chronic cml flt3 hematolog imatinib leukaemia leukem dog foot hand later left leg limb proxim rabbit radial report right leukemia lymphoblast marrow mds myelodysplast myeloid patient relaps segment upper syndrom 7: Nervous System Malformations (25) 8: Fetal Diseases (100) analysi associ brain cell control birth deliveri fetal fetu fetus develop differ gestat infant matern mother express featur gene neonat newborn placent placenta pregnanc pregnant prenat human mechan mice preterm twin week women mutat normal number requir studi syndrom tissu 1 9: Kidney Diseases (109) 10: Muscular Dystrophies (65) associ chronic clear creatinin develop dialysi diseas contract dmd dystrophi dystrophin exercis fiber gene failur famili gene glomerular kidnei muscl muscular mutat myoblast myopathi perform role skelet smc smooth strength nephropathi patient progress rcc renal train weak studi tubul tubular 11: Carcinoma, Small Cell (135) 12: Lung Neoplasms (1286) a549 adenocarcinoma alveolar associ cancer a549 adenocarcinoma alveolar bronchial cancer carcinoma case cell compar control lung cell compar includ lung non-smal non-smal non-small-cel nsclc patient pulmonari size non-small-cel nsclc observ patient pulmonari respect small studi tumor sclc small studi tumor 13: Chromosome Aberrations (688) 14: Asthma (240) aberr abnorm analysi arm breakpoint case airwai allerg allergen allergi chromosom cytogenet asthma cftr chronic conduct delet duplic gene genet karyotyp loss molecular mosaic rearrang region transloc trisomi copd cystic diseas eosinophil fibrosi ige obstruct pulmonari respiratori sever studi ventil 15: Bronchial Hyperreactivity (21) 16: Genetic Predisposition to Disease airwai allerg allergen associ (2191) allel associ diseas factor famili frequenc gene asthma cftr control cystic genet genotyp haplotyp diseas eosinophil fibrosi ige mice individu molecular mutat obstruct pulmonari respiratori polymorph popul risk snp suscept variant variat sever studi test ventil 2 17: Spherocytosis, Hereditary (9) 18: Hemophilia B (24) adult analysi caus cell child childhood analysi assai associ bleed detect children clinic defici domin factor folat genet group increas famili genet mutat new parent pediatr phenotyp level mthfr plasma popul treatment year patient platelet risk sensit studi thrombosi venou 19: Cat Diseases (53) 20: Lymphoma (224) canin cat clinic deform diagnosi diagnost b-cell case cell clinic cll diffus hodgkin human immunoglobulin larg leukemia lymphocyt lymphoid differ distal dog hand isol later left limb proxim rabbit report right lymphoma malign nhl non-hodgkin patient rituximab t-cell segment studi 21: Sphingolipidoses (1) 22: HIV Infections (534) activ basi biosynthesi catalyt conform crystal aids antiretrovir env envelop gag herp hiv enzym experi gener involv mechan molecular organ possibl process hiv-1 hsv hsv-1 human structur substrat underli immunodefici infect opn replic understand understood revers simplex viral viru virus 23: Acquired Immunodeficiency Syn- 24: Arenaviridae Infections (3) drome (123) adult care caus compar aids antiretrovir differ env envelop gag herp control frequenc health high hiv hiv-1 hsv hsv-1 human infect lead level low manag medic resist rna target viral viru year immunodefici infect new replic simplex viral viru virus 3 25: Hemophilia A (85) 26: Tooth Abnormalities (38) abnorm anomali case cleft clinic congenit defect associ bleed coagul factor fibrinogen dental develop facial famili increas lip palat folat folic homocystein leiden mthfr patient patient report respons sever plasma platelet reductas risk studi thrombin thrombosi venou vitamin syndrom teeth 27: Voice Disorders (4) 28: Tooth Loss (9) case data differ diseas follow gener incid loss caus data estim famili genet mean measur method multipl patient persist predict state group higher incid life men studi subject valu variabl mortal patient popul preval rate select studi subject women year 29: Mandibular Fractures (3) 30: Persistent Vegetative State (44) adapt case children complic condit argu articl concern conflict consent debat degre hospit patient period discuss ethic inform issu medic moral paper patient practic public question point region report select sequenc surgeri surgic temperatur research scientif social time tumour year 31: Osteosarcoma (109) 32: Syndrome (677) abnorm anomali associ case caus clinic congenit activ analysi associ bone case cell children express gene group human kit line defect disord domin famili featur inherit malform patient protein respons sarcoma stromal studi tumor mutat patient report retard sever syndrom 4 33: Hepatitis C, Chronic (100) 34: Leukemia, Myelocytic, Acute (184) aim bile biliari chronic cirrhosi duct fibrosi hbv hcv acut aml bcr-abl blast children chronic cml group imatinib leukaemia leukem hepat hepatocyt hepatoma infect liver methods patient replic viral viru virus leukemia lymphoblast marrow mds myelodysplast myeloid patient relaps syndrom 35: Intestinal Neoplasms (52) 36: Stomach Neoplasms (475) analysi cancer cell chronic develop adenocarcinoma aim associ cancer erad examin diseas express gene human increas gastric gastrointestin helicobact intestin mice mous mutat number infect intestin methods mucin mucosa pylori relat respect stomach studi ulcer patient rate tissu tumor tumour 37: Adenocarcinoma (861) 38: Esophageal Neoplasms (202) adenocarcinoma analysi cancer associ carcinoma common carcinoma cell colon colorect express gastric gene esophag frequent includ investig italian mesothelioma observ possibl lesion lung pancreat patient prostat stain studi occur occurr probabl relat report studi transmiss surviv tissu tumor transmit tumor 39: Carcinoma, Signet Ring Cell (17) 40: Rhinitis (12) cancer case cell chang compar decreas assai asthma compar control delet develop express gastric gene correl detect effect fibrosi group increas phenotyp gener genet identifi patient pylori rate report studi tissu tumor requir screen sensit signific studi subject treatment year 5 41: Corneal Diseases (42) 42: Scleritis (3) aberr ablat case conclusions cornea biolog care caus conclusions corneal correct corneal correct develop diseas health hospit lead evalu examin mean measur methods method methods patient myopia ocular patient perform refract procedur protocol servic studi system techniqu studi thick visual 43: Eye Neoplasms (40) 44: Neoplasms, Multiple Primary (84) analysi case cell clinic diagnosi associ cancer case cell describ diagnos featur group lesion method patient popul diagnosi featur literatur man multipl patient phenotyp present rare report reveal risk tumor woman rate role specimen stain studi tissu treatment tumor tumour 45: Endophthalmitis (11) 46: Melanoma (541) analysi case cataract clinic compar dai differ demonstr elong immun melanocyt melanoma microrna mirna nevi pol polymeras requir respons diseas glaucoma group higher ribozym rna rnase small transcript tumor uveal implant increas infect len measur popul vitro rate role studi 47: Adenocarcinoma, Sebaceous (3) 48: Sebaceous Gland Neoplasms (6) alpha approach carcinoma chines compar carcinoma case clinic express famili concentr control differ form format identifi individu member method frequenc method plai express normal patient phenotyp report receptor role signific strategi studi subtyp screen skin techniqu tissu tumor techniqu tumor 6 49: Glaucoma, Angle-Closure (18) 50: Glaucoma, Neovascular (6) activ anterior associ cataract adult case clinic conclusions differ diseas estim examin chamber conclusions disc examin famili implant method methods patient glaucoma implant includ pattern primari retin studi target techniqu visual year intraocular iop len methods perform studi surgeri visual 51: Conjunctival Neoplasms (13) 52: Denys-Drash Syndrome (7) aberr associ conclusions cornea abnorm anomali case chain congenit femal gene corneal correct develop examin high mean health includ individu male mutat patient measur methods ocular patient perform protein studi treatment visual year reaction report risk studi syndrom target tumor 53: Liver Neoplasms (686) 54: Carcinoma, Hepatocellular (509) bile carcinoma case cell chronic carcinogenesi carcinoma case cirrhosi correl express hcc hepat hepatocellular cell chronic correl express gene hcc hepat hepatocellular hepatocyt immunohistochem invas liver hepatocyt invas liver methods patient progress methods progress scc squamou tumor scc squamou tumor 55: Vocal Cord Paralysis (9) 56: Branchioma (5) analysi case correl develop improv absenc case clinic diagnosi event experi featur genet initi intern manag origin patient increas life loss patient perform present presenc present process rare report second qualiti rare report reveal sever signific studi sever surgeri surgic 7 57: Colonic Polyps (35) 58: Genomic Instability (191) analysi associ bac cancer cell
Load more

Recommended publications
  • Breast Cysts
    Beaumont Hospital Patient Information on Breast Cysts PRINTROOM PDF 23012017 SUP190B What are breast cysts? The breasts are made up of lobules (milk- producing glands) and ducts (tubes that carry milk to the nipple), surrounded by fatty and supportive tissue. Sometimes fluid-filled sacs develop in the breast tissue. These are breast cysts. It’s thought that they develop naturally as the breast ages and changes. Although you can develop breast cysts at any age, they are most common in women over 35 who haven’t yet reached menopause. They occur more frequently as women approach the menopause and usually resolve or are less frequent after it. However, they may persist or develop in women who take hormone replacement therapy (HRT) after menopause. Cysts can feel soft if they are near the surface of the skin, or like a hard lump if they’re deeper in the breast tissue. They can develop anywhere in the breast, but are more commonly found in the upper half. For some women cysts can feel uncomfortable or even painful. Before a period cysts may become larger, and feel sore and tender. It’s common to develop one or more cysts either in one breast or both breasts –and this is nothing to worry about. It is also common to have many cysts without knowing about them. How are they found? Cysts usually become noticeable as a lump in the breast, or are sometimes found by chance when you have a breast examination or routine mammography. When you have a breast examination your GP will sometimes be able to say whether the lump feels like a cyst.
    [Show full text]
  • Sample-11060.Pdf
    Ob/Gyn Sonography An Illustrated Review 2nd Edition Jim Baun, BS, RDMS, RVT, FSDMS Professional Ultrasound Services San Francisco, California SPECIALISTS IN ULTRASOUND EDUCATION, TEST PREPARATION, AND CONTINUING MEDICAL EDUCATION iv SPECIALISTSCopyright IN ULTRASOUND © 2016, EDUCATION, 2004 by Davies Publishing, Inc. TEST PREPARATION, AND CONTINUINGAll rights MEDICAL reserved. EDUCATION No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or mechanical, including photocopying, scanning, and recording, without prior written permission from the publisher. Davies Publishing, Inc. Michael Davies, Publisher Specialists in Ultrasound Education, Christina J. Moose, Editorial Director Test Preparation, and Continuing Charlene Locke, Production Manager Medical Education Janet Heard, Operations Manager 32 South Raymond Avenue Pasadena, California 91105-1961 Jim Baun, Illustration Phone 626-792-3046 Stephen Beebe, Illustration Facsimile 626-792-5308 Satori Design Group, Inc., Design Email [email protected] www.daviespublishing.com Notice to Users of This Publication: In the field of ultrasonography, knowledge, technique, and best practices are continually evolving. With new research and developing technologies, changes in methodologies, professional prac- tices, and medical treatment may become necessary. Sonography practitioners and other medi- cal professionals and researchers must rely on their experience and knowledge when evaluating and using information, methods,
    [Show full text]
  • Pfeiffer Syndrome Type II Discovered Perinatally
    Diagnostic and Interventional Imaging (2012) 93, 785—789 CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector LETTER / Musculoskeletal imaging Pfeiffer syndrome type II discovered perinatally: Report of an observation and review of the literature a,∗ a a a H. Ben Hamouda , Y. Tlili , S. Ghanmi , H. Soua , b c b a S. Jerbi , M.M. Souissi , H. Hamza , M.T. Sfar a Unité de néonatologie, service de pédiatrie, CHU Tahar Sfar, 5111 Mahdia, Tunisia b Service de radiologie, CHU Tahar Sfar, 5111 Mahdia, Tunisia c Service de gynéco-obstétrique, CHU Tahar Sfar, 5111 Mahdia, Tunisia Pfeiffer syndrome, described for the first time by Pfeiffer in 1964, is a rare hereditary KEYWORDS condition combining osteochondrodysplasia with craniosynostosis [1]. This syndrome is Pfeiffer syndrome; also called acrocephalosyndactyly type 5, which is divided into three sub-types. Type I Cloverleaf skull; is the classic Pfeiffer syndrome, with autosomal dominant transmission, often associated Craniosynostosis; with normal intelligence. Types II and III occur as sporadic cases in individuals who have Syndactyly; craniosynostosis with broad thumbs, broad big toes, ankylosis of the elbows and visceral Prenatal diagnosis abnormalities [2]. We report a case of Pfeiffer syndrome type II, discovered perinatally, which is distinguished from type III by the skull appearing like a cloverleaf, and we shall discuss the clinical, radiological and evolutive features and the advantage of prenatal diagnosis of this syndrome with a review of the literature. Observation The case involved a male premature baby born at 36 weeks of amenorrhoea with multiple deformities at birth. The parents were not blood-related and in good health who had two other boys and a girl with normal morphology.
    [Show full text]
  • Approach to Breast Mass
    APPROACH TO BREAST MASS Resident Author: Kathleen Doukas, MD, CCFP Faculty Advisor: Thea Weisdorf, MD, CCFP Creation Date: January 2010, Last updated: August 2013 Overview In primary care, breast lumps are a common complaint among women. In one study, 16% of women age 40-69y presented to their physician with a breast lesion over a 10-year period.1 Approximately 90% of these lesions will be benign, with fibroadenomas and cysts being the most common.2 Breast cancer must be ruled out, as one in ten woman who present with a new lump will have cancer.1 Diagnostic Considerations6 Benign: • Fibroadenoma: most common breast mass; a smooth, round, rubbery mobile mass, which is often found in young women; identifiable on US and mammogram • Breast cyst: mobile, often tender masses, which can fluctuate with the menstrual cycle; most common in premenopausal women; presence in a postmenopausal woman should raise suspicion for malignancy; ultrasound is the best method for differentiating between a cystic vs solid structure; a complex cyst is one with septations or solid components, and requires biopsy • Less common causes: Fat necrosis, intraductal papilloma, phyllodes tumor, breast abscess Premalignant: • Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia: Premalignant breast lesions with 4-6 times relative risk of developing subsequent breast cancer;8 often found incidentally on biopsy and require full excision • Carcinoma in Situ: o Ductal Carcinoma in Situ (DCIS): ~85% of in-situ breast cancers; defined as cancer confined to the duct that
    [Show full text]
  • Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years’ Experience
    Article Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years’ Experience Eiji Higashihara,*† Vicente E. Torres,*‡ Arlene B. Chapman,§ Jared J. Grantham, Kyongtae Bae,¶ Terry J. Watnick,** †† † ‡‡ ‡‡ ‡‡ 2 Shigeo Horie, Kikuo Nutahara, John Ouyang, Holly B. Krasa, Frank S. Czerwiec, for the TEMPO4 and 156-05-002 Study Investigators Summary †Kyorin University Background and objectives Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of School of Medicine, end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression Mitaka, Tokyo, Japan; ‡ in animal models. Mayo Clinic College of Medicine, Rochester, Minnesota; §Emory Design, setting, participants, and measurements This is a prospectively designed analysis of annual total kid- University School of ney volume (TKV) and thrice annual estimated GFR (eGFR) measurements, from two 3-year studies of Medicine, Atlanta, ʈ tolvaptan in 63 ADPKD subjects randomly matched 1:2 to historical controls by gender, hypertension, age, Georgia; Kansas and baseline TKV or eGFR. Prespecified end points were group differences in log-TKV (primary) and eGFR University Medical Center, Kansas City, (secondary) slopes for month 36 completers, using linear mixed model (LMM) analysis. Sensitivity analyses Kansas; ¶University of of primary and secondary end points included LMM using all subject data and mixed model repeated mea- Pittsburgh School of sures (MMRM) of change from baseline at each year. Pearson correlation tested the association between Medicine, Pittsburgh, log-TKV and eGFR changes. Pennsylvania; **Johns Hopkins University, Baltimore, Maryland; Results Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced adverse events ††Teikyo University (AEs), with AEs accounting for six of 12 withdrawals.
    [Show full text]
  • Increased Nuchal Translucency Precision Panel
    Increased Nuchal Translucency Precision Panel Overview Increased Nuchal Translucency (NT) is defined as an abnormal accumulation of fluid in the nuchal area, which is visualized as a thickened sonolucent area. It is a standardized measure obtained between 11 and 14 weeks of gestation to calculate the risk of a fetus being affected by a chromosomal aneuploidy. NT>3.5mm has been found to be associated with fetal chromosomal abnormalities and single-gene disorders as well as cardiac defects and other structural abnormalities in euploid and aneuploid fetuses. Proportionally as NT increases, even with a normal karyotype, there is a higher risk of adverse pregnancy outcomes such as miscarriage, intrauterine death, congenital heart defects and numerous other structural and genetic syndromes. There is not one single cause of increased NT, it is based on a complex and multifactorial process, linked to one or more embryonic processes. It has been shown that a persistently increased NT with a normal karyotype and aCGH has a 4-10% probability of being associated to Noonan Syndrome and/or other RASopathies using Whole Exome Sequencing (WES). However, the general tendency following detection of isolated enlarged NT in an euploid fetus is that most babies with normal detailed ultrasound examination and echocardiography will have uneventful outcomes. The Igenomix Increased Nuchal Translucency Precision Panel can be used to make a directed and accurate prenatal differential diagnosis of increased nuchal translucency in patients with or without a normal karyotype ultimately leading to a better management and prognosis of the associated comorbidities. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.
    [Show full text]
  • 27Th ANNUAL RESEARCH DAY & Henderson Lecture
    27th ANNUAL RESEARCH DAY & Henderson Lecture FRIDAY, MAY 7, 2010 8:00 a.m. to 6:30 p.m. Northrop Frye Hall, Ground Floor Victoria University, 73 Queen's Park Crescent East University of Toronto M5S 1K7 Lecturer: Jane Norman MD Professor of Maternal and Fetal Health, University of Edinburgh, UK Co-Director, Edinburgh Tommy’s Centre for Maternal and Fetal Health Research Topic: Being Born Too Soon – Do Obstetricians Have Anything To Offer? Abstract deadline: Friday, March 5, 2010 http://www.obgyn.utoronto.ca/Research/ResearchDay.htm For additional information or assistance, please contact Helen Robson at [email protected] PROGRAMME-AT-A-GLANCE (A.M.) Department of Obstetrics & Gynaecology 27th Annual Research Day, Friday, May 7, 2010 Northrop Frye Hall, Victoria University, University of Toronto, 73 Queen’s Park Crescent NF=Northrop Frye Hall Burwash Hall is located at the north end of the Victoria Quad 7:30 a.m. on Poster Set-up for Poster Session I [NF, ground floor, Rms. 004, 006, 007 & 008] 8:00 a.m. Registration & Continental Breakfast [NF, ground floor lobby] 8:25 – 8:30 a.m. Welcome: Dr. Alan Bocking, Chair [NF, ground floor Lecture Hall, Rm. 003] 8:30 – 9:45 a.m. Oral Session I (O1-O5) [NF, ground floor Lecture Hall, Rm. 003] 9:45 – 10:05 a.m. Coffee Break & Poster Session I Walkabout [NF, ground floor lobby; Rms. 004, 006, 007 & 008] 10:05 – 11:05 a.m. Poster Session I Tour [NF, Rms. 004, 006, 007 & 008] Groups A-F Poster Takedown for a.m.
    [Show full text]
  • Annualreport 2010
    AnnualReport 2010 Seth G.S. Medical College & King Edward Memorial Hospital Municipal Corporation of Greater Mumbai Convocation Ceremony of Use of smart board by 1st MBBS students Fellowship and Certificate Courses Automated chappati maker Clean KEM campaign Cardiac Ambulance Seth G.S. Medical College & King Edward Memorial Hospital Municipal Corporation of Greater Mumbai ANNUAL REPORT 2010 Concept (Front & Back cover) Dr. Sanjay Oak Director -Medical Education and Major Hospitals Professor of Pediatric Surgery Publisher Diamond Jubilee Society Trust Seth G.S. Medical College & KEM Hospital, Parel, Mumbai 400 012. Printer Urvi Compugraphics A2/248, Shah & Nahar Industrial Estate, S.J. Marg, Lower Parel (West), Mumbai 400 013. Tel.: 91 - 22 - 2494 5863 © Seth GS Medical College & KEM Hospital, 2011 Acknowledgements Smt. Shraddha Jadhav Hon. Mayor Smt. Shailaja Girkar Shri Subodh Kumar Deputy Mayor Municipal Commissioner Shri Sunil Prabhu Smt. Manisha Patankar-Mhaiskar Leader of the House Additional Municipal Commissioner (Western Suburbs) Shri Rajhans Singh Shri Aseem Gupta Leader of the Opposition Additional Municipal Commissioner (Eastern Suburbs) Shri Rahul Shewale Shri Mohan Adtani Chairman-Standing Committee Additional Municipal Commissioner (City) Smt. Ashwini Mate Shri Rajeev Jalota Chairman-Public Health Committee Additional Municipal Commissioner (Projects) Shri Parshuram (Chotu) Desai Shri Rajendra Vale Chairman-Works Committee (City) Deputy Municipal Commissioner (Estate & General Administration) Shri Anil Pawar Shri Sanjay (Nana) Ambole Chairperson - Ward Committee Municipal Councillor From the Director’s desk..... The twin institutes of the Seth GS Medical College & KEM Hospital were established in 1926 with a nationalistic spirit to cater to the “health care needs of the northern parts of the island” to be manned entirely by Indians.
    [Show full text]
  • POEMS Syndrome: an Atypical Presentation with Chronic Diarrhoea and Asthenia
    European Journal of Case Reports in Internal Medicine POEMS Syndrome: an Atypical Presentation with Chronic Diarrhoea and Asthenia Joana Alves Vaz1, Lilia Frada2, Maria Manuela Soares1, Alberto Mello e Silva1 1 Department of Internal Medicine, Egas Moniz Hospital, Lisbon, Portugal 2 Department of Gynecology and Obstetrics, Espirito Santo Hospital, Evora, Portugal Doi: 10.12890/2019_001241 - European Journal of Case Reports in Internal Medicine - © EFIM 2019 Received: 28/07/2019 Accepted: 13/11/2019 Published: 16/12/2019 How to cite this article: Alves Vaz J, Frada L, Soares MM, Mello e Silva A. POEMS syndrome: an atypical presentation with chronic diarrhoea and astenia. EJCRIM 2019;7: doi:10.12890/2019_001241. Conflicts of Interests: The Authors declare that there are no competing interest This article is licensed under a Commons Attribution Non-Commercial 4.0 License ABSTRACT POEMS syndrome is a rare paraneoplastic condition associated with polyneuropathy, organomegaly, monoclonal gammopathy, endocrine and skin changes. We report a case of a man with Castleman disease and monoclonal gammopathy, with a history of chronic diarrhoea and asthenia. Gastrointestinal involvement in POEMS syndrome is not frequently referred to in the literature and its physiopathology is not fully understood. Diagnostic criteria were met during hospitalization but considering the patient’s overall health condition, therapeutic options were limited. Current treatment for POEMS syndrome depends on the management of the underlying plasma cell disorder. This report outlines the importance of a thorough review of systems and a physical examination to allow an attempted diagnosis and appropriate treatment. LEARNING POINTS • POEMS syndrome should be suspected in the presence of peripheral polyneuropathy associated with monoclonal gammopathy; diagnostic workup is challenging and delay in treatment is very common.
    [Show full text]
  • Herbal Medicines in Pregnancy and Lactation : an Evidence-Based
    00 Prelims 1410 10/25/05 2:13 PM Page i Herbal Medicines in Pregnancy and Lactation An Evidence-Based Approach Edward Mills DPh MSc (Oxon) Director, Division of Clinical Epidemiology Canadian College of Naturopathic Medicine North York, Ontario, Canada Jean-Jacques Duguoa MSc (cand.) ND Naturopathic Doctor Toronto Western Hospital Assistant Professor Division of Clinical Epidemiology Canadian College of Naturopathic Medicine North York, Ontario, Canada Dan Perri BScPharm MD MSc Clinical Pharmacology Fellow University of Toronto Toronto, Ontario, Canada Gideon Koren MD FACMT FRCP Director of Motherisk Professor of Medicine, Pediatrics and Pharmacology University of Toronto Toronto, Ontario, Canada With a contribution from Paul Richard Saunders PhD ND DHANP 00 Prelims 1410 10/25/05 2:13 PM Page ii © 2006 Taylor & Francis Medical, an imprint of the Taylor & Francis Group First published in the United Kingdom in 2006 by Taylor & Francis Medical, an imprint of the Taylor & Francis Group, 2 Park Square, Milton Park, Abingdon, Oxon OX14 4RN Tel.: ϩ44 (0)20 7017 6000 Fax.: ϩ44 (0)20 7017 6699 E-mail: [email protected] Website: www.tandf.co.uk/medicine All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or trans- mitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP.
    [Show full text]
  • Journal of Threatened Taxa
    PLATINUM The Journal of Threatened Taxa (JoTT) is dedicated to building evidence for conservaton globally by publishing peer-reviewed artcles OPEN ACCESS online every month at a reasonably rapid rate at www.threatenedtaxa.org. All artcles published in JoTT are registered under Creatve Commons Atributon 4.0 Internatonal License unless otherwise mentoned. JoTT allows unrestricted use, reproducton, and distributon of artcles in any medium by providing adequate credit to the author(s) and the source of publicaton. Journal of Threatened Taxa Building evidence for conservaton globally www.threatenedtaxa.org ISSN 0974-7907 (Online) | ISSN 0974-7893 (Print) Review Ramifications of reproductive diseases on the recovery of the Sumatran Rhinoceros Dicerorhinus sumatrensis (Mammalia: Perissodactyla: Rhinocerotidae) Nan E. Schafer, Muhammad Agil & Zainal Z. Zainuddin 26 February 2020 | Vol. 12 | No. 3 | Pages: 15279–15288 DOI: 10.11609/jot.5390.12.3.15279-15288 For Focus, Scope, Aims, Policies, and Guidelines visit htps://threatenedtaxa.org/index.php/JoTT/about/editorialPolicies#custom-0 For Artcle Submission Guidelines, visit htps://threatenedtaxa.org/index.php/JoTT/about/submissions#onlineSubmissions For Policies against Scientfc Misconduct, visit htps://threatenedtaxa.org/index.php/JoTT/about/editorialPolicies#custom-2 For reprints, contact <[email protected]> The opinions expressed by the authors do not refect the views of the Journal of Threatened Taxa, Wildlife Informaton Liaison Development Society, Zoo Outreach Organizaton, or any of
    [Show full text]
  • Index to the NLM Classification 2011
    National Library of Medicine Classification 2011 Index Disease see Tyrosinemias 1-8 5,12-diHETE see Leukotriene B4 1,2-Benzopyrones see Coumarins 5,12-HETE see Leukotriene B4 1,2-Dibromoethane see Ethylene Dibromide 5-HT see Serotonin 1,8-Dihydroxy-9-anthrone see Anthralin 5-HT Antagonists see Serotonin Antagonists 1-Oxacephalosporin see Moxalactam 5-Hydroxytryptamine see Serotonin 1-Propanol 5-Hydroxytryptamine Antagonists see Serotonin Organic chemistry QD 305.A4 Antagonists Pharmacology QV 82 6-Mercaptopurine QV 269 1-Sar-8-Ala Angiotensin II see Saralasin 7S RNA see RNA, Small Nuclear 1-Sarcosine-8-Alanine Angiotensin II see Saralasin 8-Hydroxyquinoline see Oxyquinoline 13-cis-Retinoic Acid see Isotretinoin 8-Methoxypsoralen see Methoxsalen 15th Century History see History, 15th Century 8-Quinolinol see Oxyquinoline 16th Century History see History, 16th Century 17 beta-Estradiol see Estradiol 17-Ketosteroids WK 755 A 17-Oxosteroids see 17-Ketosteroids A Fibers see Nerve Fibers, Myelinated 17th Century History see History, 17th Century Aardvarks see Xenarthra 18th Century History see History, 18th Century Abate see Temefos 19th Century History see History, 19th Century Abattoirs WA 707 2',3'-Cyclic-Nucleotide Phosphodiesterases QU 136 Abbreviations 2,4-D see 2,4-Dichlorophenoxyacetic Acid Chemistry QD 7 2,4-Dichlorophenoxyacetic Acid General P 365-365.5 Organic chemistry QD 341.A2 Library symbols (U.S.) Z 881 2',5'-Oligoadenylate Polymerase see Medical W 13 2',5'-Oligoadenylate Synthetase By specialties (Form number 13 in any NLM
    [Show full text]